MacKenzie Realty Capital: Preferred Buybacks Paid in Stock
Some links pay us a referral fee; each one says so. Disclosure
Filing alert · free
An email when MacKenzie Realty Capital files with the SEC
An email the day MacKenzie Realty Capital files something new, with the link to the document on the SEC site.
Quick answer
MacKenzie Realty Capital, Inc. (Nasdaq: MKZR, CIK 1550913) filed its Form 10-Q for the quarter ended September 30, 2026, its first quarter of fiscal 2027, on November 16, 2026 (accession 0001140361-26-044213). It reports one preferred repurchase in the quarter: 17,546.04 Series A preferred shares at an average $24.77, $434,600 in all, paid not in cash but with 262,418 new common shares issued on July 1, 2026 at values of $1.64 to $1.70 a share. That is 14.96 common shares for each preferred share and 10.4% of the 2,512,270 common shares outstanding at June 30, 2026 (our arithmetic). The company did not file the Form 8-K that issuance required, says it is “not eligible to use Form S-3,” and its disclosure controls were “not effective.” The board suspended the preferred repurchase program on September 11, 2026, and the 10-Q reports no repurchase after July 2026. Net loss was $3,479,685 for the quarter against $3,046,894, including a $1,100,681 impairment on Satellite Place Office Building, and interest expense was 48.7% of revenue (our arithmetic). The 10-Q has no going-concern language (our search of its text), gives no NAV for the common shares, and records the November 13, 2026 sale of Woodland Corporate Center Two for $9.70 million. This is analysis of public documents, not investment, legal or tax advice.
Key takeaways
- Preferred repurchases were paid in common stock: 17,546.04 Series A shares ($434,600 at $24.77 a share on average) became 262,418 common shares issued on July 1, 2026, a year earlier 7,051.54 shares ($170,790) became 36,251 common shares. No Series B or Series C shares were repurchased in either quarter.
- The issuance was more than 5% of the common stock, so an 8-K under Item 3.02 was due within four business days. The company did not file it, and the 10-Q says it believes it is not eligible to use Form S-3 until the SEC staff grants a waiver. The 10-Q says its disclosure controls were not effective for that reason.
- The preferred repurchase program has been temporarily suspended since September 11, 2026, announced on September 30, 2026 to “better react to any strategic alternative.” The offering circular qualified on October 23, 2026 warns holders to “be prepared to hold their preferred shares indefinitely,” and it keeps the offering open for up to $71,681,755.55.
- Net loss was $3,479,685 against $3,046,894 a year earlier; the net loss attributable to common stockholders was $4,539,957, or $1.64 a share against $2.35. Revenue rose to $5,384,781 from $4,539,062, interest expense rose to $2,621,708 from $2,018,535, and FFO before allocations was a loss of $202,933 against a loss of $849,366.
- Between June 30 and September 30, 2026 total stockholders' equity fell from $43,776,005 to $40,169,118, cash rose from $3,517,313 to $5,968,324, and notes payable, net rose from $3,863,717 to $5,705,354 because of new Streeterville notes used to buy and short National Healthcare Properties shares. The Streeterville notes #4, #5 and #6 and the collateral note were repaid on November 6 and 12, 2026.
- After quarter end: Woodland Corporate Center Two sold on November 13, 2026 for $9.70 million gross, with about $5.83 million repaying its Summit Financial loan and about $3.1 million net cash to the company; Satellite Place Office Building was listed for sale in October 2026, and its lender waived a debt service covenant breach only through December 31, 2026.
- The preferred DRIP was suspended on October 2, 2026 and resumed on October 23, 2026. Series A, B and C dividends for the quarter ending December 31, 2026 were approved in the October 2 8-K. The common dividend has been suspended since May 2025, and the 10-Q publishes no estimated NAV per common share.
CSV · 103 rows
MacKenzie Realty Capital: balance sheet, results, preferred repurchases and offering, debt, Streeterville notes and filing failures from the 10-Q for September 30, 2026
103 rows from the 10-Q for the quarter ended September 30, 2026, the 8-Ks of September 30 and October 2, 2026, the offering circular of October 23, 2026 and the proxy statement, with the SEC accession on each row.
This page reads the new 10-Q against the balance sheet of June 30, 2026 and the filings of the quarter. It does not repeat the company's history, the preferred terms or the insider and mini-tender record, which are in our MacKenzie Realty Capital review. Two corrections to how the company is often described: the common stock is no longer non-traded, since it has traded on the Nasdaq Capital Market under MKZR since November 11, 2024, and the 10-Q does not publish a net asset value for it. What is unlisted, and where the news is, is the Series A, B and C preferred stock sold under Regulation A. For other Regulation A real estate offerings see our Reg A census.
What changed between June 30 and September 30, 2026
| Balance sheet (USD) | Jun 30, 2026 | Sep 30, 2026 | Change (our arithmetic) |
|---|---|---|---|
| Cash and cash equivalents | 3,517,313 | 5,968,324 | +2,451,011 |
| Total real estate assets, net | 212,687,770 | 210,331,932 | -2,355,838 |
| Investments, at fair value | 2,550,146 | 4,402,848 | +1,852,702 |
| Total assets | 235,289,800 | 236,989,604 | +1,699,804 |
| Securities sold, not yet purchased | none | 1,283,200 | +1,283,200 |
| Mortgage notes payable, net | 131,867,757 | 131,803,125 | -64,632 |
| Line of credit (affiliate) | 10,000,000 | 10,000,000 | 0 |
| Notes payable, net | 3,863,717 | 5,705,354 | +1,841,637 |
| Due to related entities | 2,197,623 | 3,068,480 | +870,857 |
| Total liabilities | 156,062,795 | 161,084,434 | +5,021,639 |
| Total stockholders' equity | 43,776,005 | 40,169,118 | -3,606,887 |
| Non-controlling interests | 35,451,000 | 35,736,052 | +285,052 |
| Common shares outstanding | 2,512,270 | 2,774,688 | +262,418 |
| Series A preferred shares outstanding | 733,447.24 | 754,059.92 | +20,612.68 |
| Series B preferred shares outstanding | 124,627.52 | 125,875.78 | +1,248.26 |
| Series C preferred shares outstanding | 54,707.09 | 60,558.77 | +5,851.68 |
The 262,418 new common shares are the whole change in the common share count, and the common share count on the November 16, 2026 cover page is the same 2,774,688. Stockholders' equity fell $3,606,887 (our arithmetic) while the accumulated deficit grew from $104,298,175 to $108,838,132. Equity here is accounting book value, built from historical cost less depreciation, and is not an estimate of what a share is worth; the 10-Q gives no such estimate.
| Three months to Sep 30 (USD) | 2026 | 2025 |
|---|---|---|
| Rental, reimbursements and other property income | 5,384,781 | 4,539,062 |
| Interest expense | 2,621,708 | 2,018,535 |
| Impairment loss (Satellite Place Office Building) | 1,100,681 | none |
| Asset management fees to related party | 802,114 | 884,766 |
| Operating loss | (4,403,884) | (3,487,885) |
| Net loss | (3,479,685) | (3,046,894) |
| Net loss attributable to common stockholders | (4,539,957) | (4,085,632) |
| Net loss per common share | (1.64) | (2.35) |
| FFO before allocations to non-controlling interest and preferred stockholders | (202,933) | (849,366) |
| AFFO before allocations to non-controlling interest and preferred stockholders | (889,150) | (1,732,348) |
Revenue grew 18.6% and interest expense grew 29.9% (our arithmetic), so interest took 48.7% of revenue against 44.5% a year earlier (our arithmetic). The 10-Q gives net cash from operating activities as $1.49 million against a use of $2.02 million a year earlier, but it also says cash received from tenants exceeded the $5.38 million of income recognized “primarily due to the collection of previously recorded rent and other receivables,” so part of the improvement is a catch-up and not a new run rate. The per-share loss of $1.64 is on 2,774,688 weighted shares against 1,738,323 a year earlier; the 2025 figure is stated after the 1-for-10 reverse split of August 4, 2025.
The preferred repurchase that was paid in common stock
The preferred repurchase program is how holders of Series A shares could ask the company to buy them back. The 10-Q shows what it did in its last quarter of operation:
| Series A preferred repurchased | Q3 to Sep 30, 2026 | Q3 to Sep 30, 2025 |
|---|---|---|
| Preferred shares repurchased | 17,546.04 | 7,051.54 |
| Value paid or stated | $434,600 at an average $24.77 | $170,790 at an average $24.22 |
| Settled by issuing common shares | 262,418 | 36,251 |
| Value per common share used | $1.64 to $1.70 | $4.03 to $5.47 |
| Common shares per preferred share (our arithmetic) | 14.96 | 5.14 |
| Date of the issuance | July 1, 2026 | September 2025 |
| Series B and Series C repurchased | none | none |
The 10-Q says the repurchases “were settled through issuance of shares of the Company’s common stock” and that “no cash or other consideration was paid by the preferred holders” except $4 of fractional shares. Dividing $434,600 by 262,418 common shares gives $1.656 a common share (our arithmetic), inside the range the company states. The 262,418 shares were 10.4% of the 2,512,270 common shares outstanding on June 30, 2026 (our arithmetic), issued in one day.
The offering circular explains why a preferred holder can end up with common shares: if the stock is listed, the company “may elect” to pay a repurchase in common stock “based on the volume weighted average price per share of common stock for the twenty (20) trading days prior to date of the repurchase.” The same circular also says a Series A holder who requests redemption may be paid in common “at an issuance price of $102.50 per share.” At $102.50 the same $434,600 would have been 4,240 shares, 62 times fewer than the 262,418 issued (our arithmetic). The 10-Q does not say which of the two rules governed these exchanges beyond giving the $1.64 to $1.70 values, so we do not know how many holders asked for stock and how many were paid it by the company's election.
The company's own explanation for stopping is in its September 30, 2026 8-K: “Our issuance of common stock in exchange for preferred shares has resulted in additional selling pressure on our common stock.” Our review notes the same board decision and the 10-K timing; the new fact in the 10-Q is the size of the issuance and the filing failure it caused.
Why the buyback is suspended and what the offering still says
| Date | Event | Source |
|---|---|---|
| Jul 1, 2026 | 262,418 common shares issued to Series A holders; no Form 8-K filed | 10-Q, Part II Item 2 |
| Sep 11, 2026 | Board temporarily suspends the preferred stock share repurchase program | 10-Q Note 13 |
| Sep 30, 2026 | Suspension announced; Maxim Group LLC named as the financial advisor bringing strategic alternatives | 8-K accession 0001550913-26-000031 |
| Oct 2, 2026 | Preferred DRIP suspended; December 2026 quarter dividends approved | 8-K accession 0001550913-26-000034 |
| Oct 23, 2026 | SEC qualifies the amended offering circular, up to $71,681,755.55 of preferred; DRIP resumed the same day | 10-Q liquidity section and Note 18 |
| Nov 16, 2026 | Annual meeting scheduled for 10 a.m. Pacific Time (four directors and the auditor); no result filing is in the EDGAR list on Nov 17, 2026 | Proxy, accession 0001550913-26-000036 |
The company has told holders what the suspension means in plain words. The offering circular filed on October 23, 2026 says holders “should be prepared to hold their preferred shares indefinitely,” that the board “may elect to continue the Repurchase Program Suspension for an extended period, terminate the share repurchase program entirely, or modify its terms,” and that it has engaged Maxim to evaluate strategic alternatives with no agreement reached. The 10-Q adds that the company “has suspended its share repurchase program and DRIP, which limits our ability to raise additional capital through these programs and may affect investor demand for our securities.” That is the company stating that the exit it ended is also the funding source it relied on.
Selling continues. In the quarter the company sold $817,500 of Series A (36,333.33 shares), $21,924 of Series B (1,000 shares) and $145,000 of Series C (5,800 shares) under the Regulation A circular, $984,424 in all (our arithmetic), against $821,511 a year earlier (our arithmetic). The circular counts $26,355,996.86 sold as of October 9, 2026 and the offering as qualified allows up to $71,681,755.55. A buyer in October 2026 is told in the same document that the repurchase program is not a source of liquidity.
Preferred dividends and the DRIP
| Quarter to Sep 30, 2026 | Per share declared | Amount declared | Note |
|---|---|---|---|
| Series A preferred | $0.375 | $274,915 | Cash; $41,072 of Series A dividends was reinvested in the DRIP |
| Series B preferred | $0.750 | $93,908 | $23,478 paid in cash and $70,430 added to the liquidation preference |
| Series C preferred | $0.563 | $32,415 | Cash; DRIP reinvested $1,163 |
| Common stock | none | none | Regular dividend suspended since May 2025 |
Dividends payable were $738,179 at September 30, 2026 against $734,333 at June 30, 2026. The cash flow discussion lists dividends paid to preferred holders of about $0.23 million (Series A), $0.02 million (Series B) and $0.03 million (Series C), roughly $0.28 million (our arithmetic) against net cash from operating activities of $1.49 million. Series B pays 12% a year but only 3% of it in cash; the other 9% accrues to the liquidation preference, which the 10-Q shows as $70,430 this quarter. The Series B accrual is not income to a holder until it is paid or the shares are redeemed.
The DRIP was suspended on October 2, 2026 and the 10-Q's Note 18 says “The Company subsequently resumed the DRIP on October 23, 2026,” the date the SEC qualified the amended circular. Our review still describes the DRIP as paused until qualification; see the section on pages of ours that need updating in the FAQ below.
Debt, cash and the Satellite Place and Woodland sales
| Loans at Sep 30, 2026 (principal unless stated) | Amount (USD) | Detail |
|---|---|---|
| Mortgage notes | 134.01 million | Scheduled maturities in fiscal years 2027 to 2033; balance-sheet figure net of costs is 131,803,125 |
| Line of credit from an affiliate of the Adviser | 10,000,000 | 10% interest and a 2% fee on each advance; limit raised to 18 million on Sep 28, 2026; maturity Dec 31, 2027; 8 million available; interest payable outstanding 1,553,337 against 1,297,781 at Jun 30, 2026 |
| Streeterville secured notes | 4,901,989 | 9% interest; 2,936,989 at Jun 30, 2026; Collateral Note repaid Nov 6, 2026 and notes #4, #5 and #6 repaid Nov 12, 2026 |
| All loans by maturity (principal) | 150,231,436 | 27,971,989 in the rest of fiscal 2027 and 34,112,367 in fiscal 2028 |
The 27,971,989 due in the rest of fiscal 2027 is 18.6% of all principal (our arithmetic). It includes the remaining balance of the Satellite Place mortgage, which the 10-Q moved into that year because of a covenant violation. At June 30, 2026 the company “was not in compliance” with the debt service coverage ratio under that Summit Financial loan; the 10-Q says “the lender agreed to temporarily waive the DSCR covenant violation through December 31, 2026, subject to the Company funding a cash collateral reserve of $245,200,” which it funded on October 23, 2026. The risk factor adds that the company intends to use its affiliate's line to repay the loan if necessary, with “no assurance that such borrowings will be available or sufficient when needed.” In October 2026 Satellite Place was listed for sale, and the quarter's $1,100,681 impairment, based on a broker opinion of value, is on that building.
Woodland Corporate Center Two, which was already held for sale at $10,338,770 of assets at September 30, 2026, was sold on November 13, 2026 for $9.70 million gross. About $5.83 million repaid the Summit Financial mortgage on it and net cash proceeds were about $3.1 million, which the company says it intends “to pay outstanding liabilities, fund ongoing operating expenses, and reduce the outstanding balance under our PRES line of credit.”
The 10-Q contains no going-concern or substantial-doubt language (we searched the saved text for both phrases and found none). The company's own statement is that it expects to fund its needs “through a combination of cash on hand, net cash provided by our property operations, new capital raised from our Series A, B and C preferred stock, new borrowings,” the affiliate line, refinancings and property sales. The first source on that list is the one the repurchase suspension and the S-3 problem make harder.
The Streeterville notes and the National Healthcare Properties trade
Part of the quarter's balance-sheet change is a trading position. In August 2026 the company issued Streeterville Capital notes #5 and #6 of $547,500 each and a $1,370,000 collateral note, at 9% interest with original issue discounts. The proceeds of notes #5 and #6 bought National Healthcare Properties shares in a tender offer at $7.27 a share, about 130,000 shares, and the collateral note supported a short sale of 80,000 NHP shares at an average $16.35. Notes of $4,901,989 were outstanding at September 30, 2026 against $2,936,989 at June 30, 2026. By November 12, 2026 the company had sold about 132,600 NHP shares and delivered shares to close the short on November 3, 2026, and repaid the collateral note on November 6 and notes #4, #5 and #6 on November 12, 2026.
This is a different business from owning offices in California. The 10-Q says NHP's Class A common stock “is listed on the NYSE,” but NHP's own 8-K says its common stock began trading on the Nasdaq Global Market under NHP on October 19, 2026. The tender price is in our records of non-traded REIT tender offers in 2026, and the issuer's side is in our NHP review and the NHP Q3 10-Q page.
Controls and the S-3: one missed 8-K
The 10-Q Item 4 concludes that the company's “disclosure controls and procedures were not effective,” citing the missing Item 3.02 8-K for the July 1, 2026 issuance. It says management began a fix: outside securities counsel must be notified before any issuance of equity securities. Part II Item 2 says the 262,418 shares “exceeded 5% of our outstanding common stock” and Part II Item 1A says the company believes it is not eligible for Form S-3, “including our existing shelf registration statement and the ATM Offering unless the SEC staff grants a waiver.” The ATM had sold 111,716.60 shares for about $1.83 million as of September 30, 2026, and the 10-Q says the company does not expect further sales until it regains eligibility. Any registered offering would have to be on Form S-11, which the company calls more costly and slower. The 10-Q does not say a waiver has been requested.
What the 10-Q does not say
- It gives no estimated NAV per common share. Our review records the company's last published estimate; since the listing the stock has a market price, which is not in the filing, so check Nasdaq for today's quote.
- It does not say how many Series A holders asked for repurchase in the quarter, how many were paid, or whether any were left unpaid before the suspension. The only figure is 17,546.04 shares repurchased, and the table shows repurchases in July only.
- It does not say whether the July issuance was at the holders' request or the company's election, or what the pricing rule was for each holder.
- It gives no terms of any strategic alternative; the circular says no agreement has been entered into.
- It does not say whether the S-3 waiver has been requested, or when preferred repurchases may restart.
Dates to watch
- Form 8-K on the November 16, 2026 annual meeting vote: due within four business days, so by November 20, 2026.
- December 31, 2026: the end of the lender's waiver on the Satellite Place covenant and the date Satellite Place moves to assets held for sale on the balance sheet.
- The December 2026 quarter preferred dividends: approved on October 2, 2026; watch whether cash is paid on schedule and whether Series B still pays 3% in cash.
- Any 8-K ending the repurchase suspension. The circular says any such action “will be publicly announced on Form 8-K.”
- The next 10-Q, for the quarter ending December 31, 2026: the first to show whether the Woodland proceeds reduced the affiliate line and whether any strategic transaction has been signed.
What a reader can do with this
This is analysis of public documents, not investment, legal or tax advice.
- Check which security you hold. The common trades on Nasdaq and can be sold at the market price. The Series A, B and C preferred cannot be sold back to the company right now. The company's offering circular says holders should be prepared to hold their preferred shares indefinitely.
- Read your last redemption confirmation. If you were repurchased in July 2026, the 10-Q says you received common shares at $1.64 to $1.70 each, not cash. Look at the share count and the date on your statement and compare them with the 262,418 shares issued on July 1, 2026; tax treatment of a stock-for-preferred exchange is a question for your tax preparer.
- Know what the preferred ranks against. The company's loans total $150.2 million of principal and sit ahead of any preferred holder; our review sets out how the three series rank against each other.
- Size the position. For a retirement account holding illiquid preferred shares, see illiquid IRA assets and required distributions. To see how other non-traded REITs pay repurchases, compare the NAV REIT redemption status table and our census of non-traded REIT 10-Qs.
If a large part of your portfolio sits in a preferred stock you cannot sell back to the issuer, or you are weighing the tax on a sale or on a move to heirs, a second opinion on your own numbers may help.
FAQ
All figures are from SEC filings of MacKenzie Realty Capital, Inc. (CIK 1550913) read on November 17, 2026: Form 10-Q for the quarter ended September 30, 2026 (accession 0001140361-26-044213, filed November 16, 2026), Form 8-K of September 30, 2026 (0001550913-26-000031), Form 8-K of October 2, 2026 (0001550913-26-000034), the offering circular filed October 23, 2026 (0001582328-26-000018), the proxy statement of October 2, 2026 (0001550913-26-000036) and, for NHP's listing venue, the National Healthcare Properties 8-K filed October 22, 2026 (0001561032-26-000068). Quotations are copied from those documents. Our arithmetic is labelled in the text. This is analysis of public documents, not investment, legal or tax advice.